The
picture to your left is showing immunofluorescence of the human glioma cell
line. (View more pictures here)
A
European based pharmaceutical company called GW Pharmaceuticals is set to
commence its first phase of clinical trials for the treatment of Glioblastoma
Multiforme (GBM). It’s a bio-pharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its proprietary
cannabinoid product platform.
According
to the New England Journal of Medicine, GBM accounts for approximately
50% of the 22,500 new cases of brain cancer diagnosed in the United States
alone each year.(1) Treatment with regards to brain cancer are very limited
which makes the study of cannabis and its effect on brain tumors crucial.
It’s
about time, isn’t it? For several years now, pre-clinical research conducted by
multiple scientists and universities all over the world have demonstrated that
cannabinoids inhibit the viability of glioma cells both in vitro and in vivo. This
happens through the process of apoptosis, or programmed cell death. Cannabis
has successfully demonstrated tumor growth-inhibiting action and an improvement
in the therapeutic efficacy of temozolomide, a standard treatment for glioma.
GW pharmaceuticals have also followed this research and also conduct it
themselves. As a result they’ve shown tumor response to be positively
associated with tissue levels of cannabinoids.
We
are very excited about moving this compound into further human study and the
prospects of cannabinoids as new anti-cancer treatments. This is GW’s first
clinical study of cannabinoids as a potential treatment to inhibit tumor
growth. We believe this clinical program demonstrates the flexibility and broad
application of GW’s cannabinoids platform to treat significant, unmet
therapeutic needs. – Dr Steven Wright, Director of Research and Development at
GW
The
study will involve 20 patients, it will be a two-part study with an open-label
phase to assess safety and tolerability of GW cannabinoids in combination with
temozolomide, and a double-blind, randomized, placebo-controlled phase with
patients randomized to active or placebo.
The study objective is to assess the
tolerability, safety, and pharmacodynamics of a mixture of two principal
cannabinoids, THC and CBD in a 1:1 allocation ration, in combination with
temozolomide in patients with recurrent GBM.
Unfortunately
the study won’t be entirely cannabis, as mentioned earlier. It will in
combination with temozolomide, an oral chemotherapy drug. Who knows what effect
this may have with regards to using cannabis as treatment, but we will find
out. Prior studies indicate that it (cannabis) does nothing but help.
Earlier
I published an article outlining four medical studies that prove cannabis can
be an effective treatment, and even cure for brain cancer. Here (below) they
are again just in-case you missed it. It’s potential benefits are not limited
to brain cancer, but all kinds of cancer that suggest a massive amount of human
clinical trials should begin. Take a look at the top 20 medical studies that prove cannabis can cure
cancer.
In
my opinion, many human trials have already been conducted outside of the
medical field. A large number of people have used cannabis to treat their
cancer, and have been successful in doing so. It’s very hard to trust
pharmaceutical companies these days. Home grown GMO and pesticide free cannabis
would be ideal, and don’t forget that the best method of ingestion is eating it as opposed to smoking it.
Hopefully
this article sparks you to further your research on the healing properties of
this plant if you’re interested. It’s a gift from nature and should not be
taken lightly when it comes to its medicinal properties. It seems nature has a
cure for everything, but our medicine has become an industry. I am a big
believer that everything has a cure.
1.
A study published in the British Journal of Cancer, conducted
by the Department of Biochemistry and Molecular Biology at Complutense
University in Madrid, this study determined that Tetrahydrocannabinol (THC) and
other cannabinoids inhibit tumour growth. They were responsible for the first
clinical study aimed at assessing cannabinoid antitumoral action. Cannabinoid
delivery was safe and was achieved with zero psychoactive effects. THC was
found to decrease tumour cells in two out of the nine patients.
2. A study published in The Journal of Neuroscience examined the
biochemical events in both acute neuronal damage and in slowly progressive,
neurodegenerative diseases. They conducted a magnetic resonance imaging study
that looked at THC (the main active compound in marijuana) and found that it
reduced neuronal injury in rats. The results of this study provide evidence that
the cannabinoid system can serve to protect the brain against
neurodegeneration.
3. A study published in The Journal of Pharmacology And Experimental Therapeutics already
acknowledged the fact that cannabinoids have been shown to possess antitumor
properties. This study examined the effect of cannabidiol (CBD, non
psychoactive cannabinoid compound) on human glioma cell lines. The addition of
cannabidiol led to a dramatic drop in the viability of glioma cells. Glioma is
the word used to describe a brain tumour. The study concluded that
cannabidiol was able to produce a significant antitumor activity.
4. A study published in the journal Molecular Cancer Therapeutics outlines how
brain tumours are highly resistant to current anticancer treatments, which
makes it crucial to find new therapeutic strategies aimed at improving the poor
prognosis of patients suffering from this disease. This study also demonstrated
the reversal of tumour activity in Glioblastoma multiforme.
Sources:New England Journal of Medicine.GW Pharmaceuticals,Department of Biochemistry and Molecular Biology at Complutense
University in Madrid,The Journal of Pharmacology And Experimental Therapeutics,The Journal of Neuroscience.
Watch this Video Link:
The picture to your left is showing immunofluorescence of the human glioma cell line. (View more pictures here)
A European based pharmaceutical company
called GW Pharmaceuticals is set to commence its first phase of clinical
trials for the treatment of Glioblastoma Multiforme (GBM). It’s a
bio-pharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform.
According to the New England Journal of Medicine, GBM
accounts for approximately 50% of the 22,500 new cases of brain cancer
diagnosed in the United States alone each year.(1) Treatment with
regards to brain cancer are very limited which makes the study of
cannabis and its effect on brain tumors crucial.
It’s about time, isn’t it? For several
years now, pre-clinical research conducted by multiple scientists and
universities all over the world have demonstrated that cannabinoids
inhibit the viability of glioma cells both in vitro and in vivo. This
happens through the process of apoptosis, or programmed cell death.
Cannabis has successfully demonstrated tumor growth-inhibiting action
and an improvement in the therapeutic efficacy of temozolomide, a
standard treatment for glioma. GW pharmaceuticals have also followed
this research and also conduct it themselves. As a result they’ve shown
tumor response to be positively associated with tissue levels of
cannabinoids.
We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW’s first clinical study of cannabinoids as a potential treatment to inhibit tumor growth. We believe this clinical program demonstrates the flexibility and broad application of GW’s cannabinoids platform to treat significant, unmet therapeutic needs. – Dr Steven Wright, Director of Research and Development at GW
The study will involve 20 patients, it
will be a two-part study with an open-label phase to assess safety and
tolerability of GW cannabinoids in combination with temozolomide, and a
double-blind, randomized, placebo-controlled phase with patients
randomized to active or placebo.
The study objective is to assess the tolerability, safety, and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ration, in combination with temozolomide in patients with recurrent GBM.
Unfortunately the study won’t be
entirely cannabis, as mentioned earlier. It will in combination with
temozolomide, an oral chemotherapy drug. Who knows what effect this may
have with regards to using cannabis as treatment, but we will find out.
Prior studies indicate that it (cannabis) does nothing but help.
Earlier I published an article outlining
four medical studies that prove cannabis can be an effective treatment,
and even cure for brain cancer. Here (below) they are again just
in-case you missed it. It’s potential benefits are not limited to brain
cancer, but all kinds of cancer that suggest a massive amount of human
clinical trials should begin. Take a look at the top 20 medical studies that prove cannabis can cure cancer.
In my opinion, many human trials have
already been conducted outside of the medical field. A large number of
people have used cannabis to treat their cancer, and have been
successful in doing so. It’s very hard to trust pharmaceutical companies
these days. Home grown GMO and pesticide free cannabis would be ideal,
and don’t forget that the best method of ingestion is eating it as opposed to smoking it.
Hopefully this article sparks you to
further your research on the healing properties of this plant if you’re
interested. It’s a gift from nature and should not be taken lightly when
it comes to its medicinal properties. It seems nature has a cure for
everything, but our medicine has become an industry. I am a big believer
that everything has a cure.
1. A study published in the British Journal of Cancer, conducted
by the Department of Biochemistry and Molecular Biology at Complutense
University in Madrid, this study determined that Tetrahydrocannabinol
(THC) and other cannabinoids inhibit tumour growth. They were
responsible for the first clinical study aimed at assessing cannabinoid
antitumoral action. Cannabinoid delivery was safe and was achieved with
zero psychoactive effects. THC was found to decrease tumour cells in two
out of the nine patients.
2. A study published in The Journal of Neuroscience examined
the biochemical events in both acute neuronal damage and in slowly
progressive, neurodegenerative diseases. They conducted a magnetic
resonance imaging study that looked at THC (the main active compound in
marijuana) and found that it reduced neuronal injury in rats. The
results of this study provide evidence that the cannabinoid system can
serve to protect the brain against neurodegeneration.
3. A study published in The Journal of Pharmacology And Experimental Therapeutics already
acknowledged the fact that cannabinoids have been shown to possess
antitumor properties. This study examined the effect of cannabidiol
(CBD, non psychoactive cannabinoid compound) on human glioma cell lines.
The addition of cannabidiol led to a dramatic drop in the viability of
glioma cells. Glioma is the word used to describe a brain tumour. The
study concluded that cannabidiol was able to produce a significant
antitumor activity.
4. A study published in the journal Molecular Cancer Therapeutics outlines
how brain tumours are highly resistant to current anticancer
treatments, which makes it crucial to find new therapeutic strategies
aimed at improving the poor prognosis of patients suffering from this
disease. This study also demonstrated the reversal of tumour activity in
Glioblastoma multiforme.
Sources:
- See more at:
http://www.collective-evolution.com/2013/11/14/first-ever-human-trials-to-be-conducted-using-cannabis-to-treat-brain-cancer/#sthash.MAfa0LRx.dpuf
The picture to your left is showing immunofluorescence of the human glioma cell line. (View more pictures here)
A European based pharmaceutical company
called GW Pharmaceuticals is set to commence its first phase of clinical
trials for the treatment of Glioblastoma Multiforme (GBM). It’s a
bio-pharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform.
According to the New England Journal of Medicine, GBM
accounts for approximately 50% of the 22,500 new cases of brain cancer
diagnosed in the United States alone each year.(1) Treatment with
regards to brain cancer are very limited which makes the study of
cannabis and its effect on brain tumors crucial.
It’s about time, isn’t it? For several
years now, pre-clinical research conducted by multiple scientists and
universities all over the world have demonstrated that cannabinoids
inhibit the viability of glioma cells both in vitro and in vivo. This
happens through the process of apoptosis, or programmed cell death.
Cannabis has successfully demonstrated tumor growth-inhibiting action
and an improvement in the therapeutic efficacy of temozolomide, a
standard treatment for glioma. GW pharmaceuticals have also followed
this research and also conduct it themselves. As a result they’ve shown
tumor response to be positively associated with tissue levels of
cannabinoids.
We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW’s first clinical study of cannabinoids as a potential treatment to inhibit tumor growth. We believe this clinical program demonstrates the flexibility and broad application of GW’s cannabinoids platform to treat significant, unmet therapeutic needs. – Dr Steven Wright, Director of Research and Development at GW
The study will involve 20 patients, it
will be a two-part study with an open-label phase to assess safety and
tolerability of GW cannabinoids in combination with temozolomide, and a
double-blind, randomized, placebo-controlled phase with patients
randomized to active or placebo.
The study objective is to assess the tolerability, safety, and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ration, in combination with temozolomide in patients with recurrent GBM.
Unfortunately the study won’t be
entirely cannabis, as mentioned earlier. It will in combination with
temozolomide, an oral chemotherapy drug. Who knows what effect this may
have with regards to using cannabis as treatment, but we will find out.
Prior studies indicate that it (cannabis) does nothing but help.
Earlier I published an article outlining
four medical studies that prove cannabis can be an effective treatment,
and even cure for brain cancer. Here (below) they are again just
in-case you missed it. It’s potential benefits are not limited to brain
cancer, but all kinds of cancer that suggest a massive amount of human
clinical trials should begin. Take a look at the top 20 medical studies that prove cannabis can cure cancer.
In my opinion, many human trials have
already been conducted outside of the medical field. A large number of
people have used cannabis to treat their cancer, and have been
successful in doing so. It’s very hard to trust pharmaceutical companies
these days. Home grown GMO and pesticide free cannabis would be ideal,
and don’t forget that the best method of ingestion is eating it as opposed to smoking it.
Hopefully this article sparks you to
further your research on the healing properties of this plant if you’re
interested. It’s a gift from nature and should not be taken lightly when
it comes to its medicinal properties. It seems nature has a cure for
everything, but our medicine has become an industry. I am a big believer
that everything has a cure.
1. A study published in the British Journal of Cancer, conducted
by the Department of Biochemistry and Molecular Biology at Complutense
University in Madrid, this study determined that Tetrahydrocannabinol
(THC) and other cannabinoids inhibit tumour growth. They were
responsible for the first clinical study aimed at assessing cannabinoid
antitumoral action. Cannabinoid delivery was safe and was achieved with
zero psychoactive effects. THC was found to decrease tumour cells in two
out of the nine patients.
2. A study published in The Journal of Neuroscience examined
the biochemical events in both acute neuronal damage and in slowly
progressive, neurodegenerative diseases. They conducted a magnetic
resonance imaging study that looked at THC (the main active compound in
marijuana) and found that it reduced neuronal injury in rats. The
results of this study provide evidence that the cannabinoid system can
serve to protect the brain against neurodegeneration.
3. A study published in The Journal of Pharmacology And Experimental Therapeutics already
acknowledged the fact that cannabinoids have been shown to possess
antitumor properties. This study examined the effect of cannabidiol
(CBD, non psychoactive cannabinoid compound) on human glioma cell lines.
The addition of cannabidiol led to a dramatic drop in the viability of
glioma cells. Glioma is the word used to describe a brain tumour. The
study concluded that cannabidiol was able to produce a significant
antitumor activity.
4. A study published in the journal Molecular Cancer Therapeutics outlines
how brain tumours are highly resistant to current anticancer
treatments, which makes it crucial to find new therapeutic strategies
aimed at improving the poor prognosis of patients suffering from this
disease. This study also demonstrated the reversal of tumour activity in
Glioblastoma multiforme.
Sources:
- See more at:
http://www.collective-evolution.com/2013/11/14/first-ever-human-trials-to-be-conducted-using-cannabis-to-treat-brain-cancer/#sthash.MAfa0LRx.dpuf
The picture to your left is showing immunofluorescence of the human glioma cell line. (View more pictures here)
A European based pharmaceutical company
called GW Pharmaceuticals is set to commence its first phase of clinical
trials for the treatment of Glioblastoma Multiforme (GBM). It’s a
bio-pharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform.
According to the New England Journal of Medicine, GBM
accounts for approximately 50% of the 22,500 new cases of brain cancer
diagnosed in the United States alone each year.(1) Treatment with
regards to brain cancer are very limited which makes the study of
cannabis and its effect on brain tumors crucial.
It’s about time, isn’t it? For several
years now, pre-clinical research conducted by multiple scientists and
universities all over the world have demonstrated that cannabinoids
inhibit the viability of glioma cells both in vitro and in vivo. This
happens through the process of apoptosis, or programmed cell death.
Cannabis has successfully demonstrated tumor growth-inhibiting action
and an improvement in the therapeutic efficacy of temozolomide, a
standard treatment for glioma. GW pharmaceuticals have also followed
this research and also conduct it themselves. As a result they’ve shown
tumor response to be positively associated with tissue levels of
cannabinoids.
We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW’s first clinical study of cannabinoids as a potential treatment to inhibit tumor growth. We believe this clinical program demonstrates the flexibility and broad application of GW’s cannabinoids platform to treat significant, unmet therapeutic needs. – Dr Steven Wright, Director of Research and Development at GW
The study will involve 20 patients, it
will be a two-part study with an open-label phase to assess safety and
tolerability of GW cannabinoids in combination with temozolomide, and a
double-blind, randomized, placebo-controlled phase with patients
randomized to active or placebo.
The study objective is to assess the tolerability, safety, and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ration, in combination with temozolomide in patients with recurrent GBM.
Unfortunately the study won’t be
entirely cannabis, as mentioned earlier. It will in combination with
temozolomide, an oral chemotherapy drug. Who knows what effect this may
have with regards to using cannabis as treatment, but we will find out.
Prior studies indicate that it (cannabis) does nothing but help.
Earlier I published an article outlining
four medical studies that prove cannabis can be an effective treatment,
and even cure for brain cancer. Here (below) they are again just
in-case you missed it. It’s potential benefits are not limited to brain
cancer, but all kinds of cancer that suggest a massive amount of human
clinical trials should begin. Take a look at the top 20 medical studies that prove cannabis can cure cancer.
In my opinion, many human trials have
already been conducted outside of the medical field. A large number of
people have used cannabis to treat their cancer, and have been
successful in doing so. It’s very hard to trust pharmaceutical companies
these days. Home grown GMO and pesticide free cannabis would be ideal,
and don’t forget that the best method of ingestion is eating it as opposed to smoking it.
Hopefully this article sparks you to
further your research on the healing properties of this plant if you’re
interested. It’s a gift from nature and should not be taken lightly when
it comes to its medicinal properties. It seems nature has a cure for
everything, but our medicine has become an industry. I am a big believer
that everything has a cure.
1. A study published in the British Journal of Cancer, conducted
by the Department of Biochemistry and Molecular Biology at Complutense
University in Madrid, this study determined that Tetrahydrocannabinol
(THC) and other cannabinoids inhibit tumour growth. They were
responsible for the first clinical study aimed at assessing cannabinoid
antitumoral action. Cannabinoid delivery was safe and was achieved with
zero psychoactive effects. THC was found to decrease tumour cells in two
out of the nine patients.
2. A study published in The Journal of Neuroscience examined
the biochemical events in both acute neuronal damage and in slowly
progressive, neurodegenerative diseases. They conducted a magnetic
resonance imaging study that looked at THC (the main active compound in
marijuana) and found that it reduced neuronal injury in rats. The
results of this study provide evidence that the cannabinoid system can
serve to protect the brain against neurodegeneration.
3. A study published in The Journal of Pharmacology And Experimental Therapeutics already
acknowledged the fact that cannabinoids have been shown to possess
antitumor properties. This study examined the effect of cannabidiol
(CBD, non psychoactive cannabinoid compound) on human glioma cell lines.
The addition of cannabidiol led to a dramatic drop in the viability of
glioma cells. Glioma is the word used to describe a brain tumour. The
study concluded that cannabidiol was able to produce a significant
antitumor activity.
4. A study published in the journal Molecular Cancer Therapeutics outlines
how brain tumours are highly resistant to current anticancer
treatments, which makes it crucial to find new therapeutic strategies
aimed at improving the poor prognosis of patients suffering from this
disease. This study also demonstrated the reversal of tumour activity in
Glioblastoma multiforme.
Sources:
- See more at:
http://www.collective-evolution.com/2013/11/14/first-ever-human-trials-to-be-conducted-using-cannabis-to-treat-brain-cancer/#sthash.MAfa0LRx.dpuf
The picture to your left is showing immunofluorescence of the human glioma cell line. (View more pictures here)
A European based pharmaceutical company
called GW Pharmaceuticals is set to commence its first phase of clinical
trials for the treatment of Glioblastoma Multiforme (GBM). It’s a
bio-pharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform.
According to the New England Journal of Medicine, GBM
accounts for approximately 50% of the 22,500 new cases of brain cancer
diagnosed in the United States alone each year.(1) Treatment with
regards to brain cancer are very limited which makes the study of
cannabis and its effect on brain tumors crucial.
It’s about time, isn’t it? For several
years now, pre-clinical research conducted by multiple scientists and
universities all over the world have demonstrated that cannabinoids
inhibit the viability of glioma cells both in vitro and in vivo. This
happens through the process of apoptosis, or programmed cell death.
Cannabis has successfully demonstrated tumor growth-inhibiting action
and an improvement in the therapeutic efficacy of temozolomide, a
standard treatment for glioma. GW pharmaceuticals have also followed
this research and also conduct it themselves. As a result they’ve shown
tumor response to be positively associated with tissue levels of
cannabinoids.
We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW’s first clinical study of cannabinoids as a potential treatment to inhibit tumor growth. We believe this clinical program demonstrates the flexibility and broad application of GW’s cannabinoids platform to treat significant, unmet therapeutic needs. – Dr Steven Wright, Director of Research and Development at GW
The study will involve 20 patients, it
will be a two-part study with an open-label phase to assess safety and
tolerability of GW cannabinoids in combination with temozolomide, and a
double-blind, randomized, placebo-controlled phase with patients
randomized to active or placebo.
The study objective is to assess the tolerability, safety, and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ration, in combination with temozolomide in patients with recurrent GBM.
Unfortunately the study won’t be
entirely cannabis, as mentioned earlier. It will in combination with
temozolomide, an oral chemotherapy drug. Who knows what effect this may
have with regards to using cannabis as treatment, but we will find out.
Prior studies indicate that it (cannabis) does nothing but help.
Earlier I published an article outlining
four medical studies that prove cannabis can be an effective treatment,
and even cure for brain cancer. Here (below) they are again just
in-case you missed it. It’s potential benefits are not limited to brain
cancer, but all kinds of cancer that suggest a massive amount of human
clinical trials should begin. Take a look at the top 20 medical studies that prove cannabis can cure cancer.
In my opinion, many human trials have
already been conducted outside of the medical field. A large number of
people have used cannabis to treat their cancer, and have been
successful in doing so. It’s very hard to trust pharmaceutical companies
these days. Home grown GMO and pesticide free cannabis would be ideal,
and don’t forget that the best method of ingestion is eating it as opposed to smoking it.
Hopefully this article sparks you to
further your research on the healing properties of this plant if you’re
interested. It’s a gift from nature and should not be taken lightly when
it comes to its medicinal properties. It seems nature has a cure for
everything, but our medicine has become an industry. I am a big believer
that everything has a cure.
1. A study published in the British Journal of Cancer, conducted
by the Department of Biochemistry and Molecular Biology at Complutense
University in Madrid, this study determined that Tetrahydrocannabinol
(THC) and other cannabinoids inhibit tumour growth. They were
responsible for the first clinical study aimed at assessing cannabinoid
antitumoral action. Cannabinoid delivery was safe and was achieved with
zero psychoactive effects. THC was found to decrease tumour cells in two
out of the nine patients.
2. A study published in The Journal of Neuroscience examined
the biochemical events in both acute neuronal damage and in slowly
progressive, neurodegenerative diseases. They conducted a magnetic
resonance imaging study that looked at THC (the main active compound in
marijuana) and found that it reduced neuronal injury in rats. The
results of this study provide evidence that the cannabinoid system can
serve to protect the brain against neurodegeneration.
3. A study published in The Journal of Pharmacology And Experimental Therapeutics already
acknowledged the fact that cannabinoids have been shown to possess
antitumor properties. This study examined the effect of cannabidiol
(CBD, non psychoactive cannabinoid compound) on human glioma cell lines.
The addition of cannabidiol led to a dramatic drop in the viability of
glioma cells. Glioma is the word used to describe a brain tumour. The
study concluded that cannabidiol was able to produce a significant
antitumor activity.
4. A study published in the journal Molecular Cancer Therapeutics outlines
how brain tumours are highly resistant to current anticancer
treatments, which makes it crucial to find new therapeutic strategies
aimed at improving the poor prognosis of patients suffering from this
disease. This study also demonstrated the reversal of tumour activity in
Glioblastoma multiforme.
Sources:
- See more at:
http://www.collective-evolution.com/2013/11/14/first-ever-human-trials-to-be-conducted-using-cannabis-to-treat-brain-cancer/#sthash.MAfa0LRx.dpuf
No comments:
Post a Comment